secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001140361-25-000943
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio reports early Attruby demand: 430 scripts from 248 physicians; three Phase 3 trials fully enrolled
--------------------------------------------------------------------------------

- Attruby (acoramidis) approved Nov 22, 2024; 430 prescriptions by 248 unique HCPs since launch.
- Three Phase 3 trials fully enrolled: FORTIFY (LGMD2I/R9, n=112), CALIBRATE (ADH1, n=70), PROPEL 3 (achondroplasia, n=114).
- Cash $406M last quarter; received $500M upon acoramidis FDA approval from royalty facility; expects $105M milestones in 1H 2025.
- Milestones: EU/Japan acoramidis approvals in 1H 2025; topline readouts FORTIFY & CALIBRATE in 2H 2025; PROPEL 3 LPLV in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125000943/0001140361-25-000943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125000943/ef20041481_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer